Search Results

You are looking at 171 - 180 of 490 items for :

  • "paclitaxel" x
  • Refine by Access: All x
Clear All
Full access

Treating Triple-Negative Breast Cancer: Where Are We?

Aki Morikawa and Andrew D. Seidman

. Microtubule-Targeting Agents Based on the TNBC subtypes, the basal-like types are postulated to respond well to taxanes because of their expression of proliferation genes. 21 Efficacy of paclitaxel specifically for TNBC (compared with non-TNBC) has been

Full access

Is the Preoperative Setting an Appropriate Platform for Drug Approval in Breast Cancer?

Virginia G. Kaklamani and William J. Gradishar

(standard dose), or a combination of both agents (lapatinib, 1000 mg/d plus standard trastuzumab dosing). 7 The anti-HER2 therapy was administered alone for the first 6 weeks, at which point weekly paclitaxel was added to the assigned anti-HER2 therapy for

Full access

Metastatic Mucinous Ovarian Cancer and Treatment Decisions Based on Histology and Molecular Markers Rather Than the Primary Location

Angela Jain, Paula D. Ryan, and Michael V. Seiden

this point showed that liver metastases had completely calcified without evidence of new disease ( Figure 1 ). With the goal of increasing tumor response, weekly paclitaxel was added to trastuzumab. Over 6 weeks, the CEA continued to trend down to 496

Full access

Therapeutically Induced Changes in HER2, HER3, and EGFR Protein Expression for Treatment Guidance

Shankar Sellappan, Adele Blackler, Wei-Li Liao, Emily O'Day, Peng Xu, Sheeno Thyparambil, Fabiola Cecchi, Todd Hembrough, and Daniel V.T. Catenacci

now 358 and 266 amol/mcg, respectively ( Figure 1B ). After bleeding was controlled, treatment was initiated with paclitaxel, trastuzumab, and lapatinib, a dual HER2/EGFR tyrosine kinase inhibitor. 8 – 10 This regimen led to continued tumor reduction

Full access

EGFR-Mutant Non–Small Cell Lung Cancer in the Era of Precision Medicine: Importance of Germline EGFR T790M Testing

Ammar Sukari, Misako Nagasaka, and Erin Wakeling

chemotherapy with carboplatin and paclitaxel. She then presented to our institution. Given the deferring histology, we obtained NGS on the adrenal gland biopsy, which reported similar molecular signature with EGFR exon 19 deletion (E746 del) and T790M. She

Full access

Part 1: Abstracts From the NCCN 18th Annual Conference: Advancing the Standard of Cancer Care™

Nanoparticle Albumin Bound (nab)-Paclitaxel Plus Carboplatin Followed by Doxorubicin Plus Cyclophosphamide (AC) in Triple-Negative Breast Cancer Jasgit C. Sachdev, a Jessica Snider, a Lee Schwartzberg, b Robyn Young, c Furhan Yunus, a Jeffrey Allen, a

Full access

EGFR Exon 19 Deletion in Pancreatic Adenocarcinoma Responds to Erlotinib, Followed by T790M-Mediated Resistance

Michael Cecchini, Jeffrey Sklar, and Jill Lacy

advances in the treatment of metastatic PDAC with 5-fluorouracil (5FU), irinotecan, oxaliplatin, and leucovorin (FOLFIRINOX) or gemcitabine plus nab-paclitaxel, median survival remains <1 year. 2 , 3 Moreover, second-line treatment options are of limited

Full access

Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology

Margaret A. Tempero, Mokenge P. Malafa, Mahmoud Al-Hawary, Horacio Asbun, Andrew Bain, Stephen W. Behrman, Al B. Benson III, Ellen Binder, Dana B. Cardin, Charles Cha, E. Gabriela Chiorean, Vincent Chung, Brian Czito, Mary Dillhoff, Efrat Dotan, Cristina R. Ferrone, Jeffrey Hardacre, William G. Hawkins, Joseph Herman, Andrew H. Ko, Srinadh Komanduri, Albert Koong, Noelle LoConte, Andrew M. Lowy, Cassadie Moravek, Eric K. Nakakura, Eileen M. O'Reilly, Jorge Obando, Sushanth Reddy, Courtney Scaife, Sarah Thayer, Colin D. Weekes, Robert A. Wolff, Brian M. Wolpin, Jennifer Burns, and Susan Darlow

indicated that the benefit of gemcitabine combination chemotherapy is predominantly seen in patients with good PS. 51 – 53 Gemcitabine Plus Albumin-Bound Paclitaxel: Albumin-bound paclitaxel is a nanoparticle form of paclitaxel. In a phase I/II trial, 67

Full access

Management of Advanced Ovarian, Fallopian Tube, and Primary Peritoneal Cancers

Presented by: Joyce F. Liu

with different clinical and genomic characteristics, which may influence response to treatments beyond the standard carboplatin/paclitaxel regimen. Genetic testing of newly diagnosed patients not only informs patient care but also prompts cascade

Full access

Esophageal and Esophagogastric Junction Cancers, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology

Jaffer A. Ajani, Thomas A. D’Amico, David J. Bentrem, David Cooke, Carlos Corvera, Prajnan Das, Peter C. Enzinger, Thomas Enzler, Farhood Farjah, Hans Gerdes, Michael Gibson, Patrick Grierson, Wayne L. Hofstetter, David H. Ilson, Shadia Jalal, Rajesh N. Keswani, Sunnie Kim, Lawrence R. Kleinberg, Samuel Klempner, Jill Lacy, Frank Licciardi, Quan P. Ly, Kristina A. Matkowskyj, Michael McNamara, Aaron Miller, Sarbajit Mukherjee, Mary F. Mulcahy, Darryl Outlaw, Kyle A. Perry, Jose Pimiento, George A. Poultsides, Scott Reznik, Robert E. Roses, Vivian E. Strong, Stacey Su, Hanlin L. Wang, Georgia Wiesner, Christopher G. Willett, Danny Yakoub, Harry Yoon, Nicole R. McMillian, and Lenora A. Pluchino

options to the standard DCF regimen for first-line therapy. Additional regimens for first-line therapy include paclitaxel with either carboplatin or cisplatin, 121 – 123 docetaxel with cisplatin, 115 , 124 or single-agent fluoropyrimidine (fluorouracil